EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML)

EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) is organized by European Hematology Association (EHA) and will be held from Apr 25 - 26, 2025 at Mercure Hotel MOA Berlin, Berlin, Germany.

Overview:
The?EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias?(sAML) will focus on:

• Therapy-related AML
• AML evolving from a previous myeloid disease (such as MDS or MFS/MPN)

Special attention will be given to:

• Clonal hematopoiesis and clonal evolution mechanisms that play a significant role in disease ontogenesis
• Special clinical situations
• Treatment

Program:
The meeting will cover intrinsic and extrinsic pathogenetic mechanisms, including:

• Susceptibility factors to sAML (such as germ-line and acquired molecular lesions)
• The role of the bone marrow microenvironment

It will also cover clinically important aspects and special situations, such as:

• sAML following childhood malignancies
• Leukemogenic effects of drugs
• Prevention/surveillance strategies
• sAML following gene therapy
• CAR-T cell therapy for sAML
• AML of donor origin in the context of allogeneic stem cell transplantation
• Current treatment options for sAML

Major experts in the molecular characterization of sAML and the translational consequences in disease diagnosis, management, and treatment will join the meeting and be part of an intensive scientific exchange.

Learning Objectives:
After attending this meeting, participants will be able to:

• Classify sAML and apply current prognostic stratification tools
• Identify patient with germ-line and acquired predisposition to sAML and other risk factor for sAML development
• Design prevention and surveillance programs
• Understand the mechanisms of clonal progression from other myeloid diseases and sAML development as a result of cancer treatment
• Explain the role of bone marrow microenvironment
• Discuss innovative treatment approaches

With this meeting, we would particularly encourage young researchers and clinician scientists to present their data on sAML in one of the abstract or poster sessions.

EHA Curriculum sections covered:
Primary

• Myeloid malignancies: Acute myeloid leukemia (secondary AML).

Secondary

• Non-malignant disorders: BM failure.
• Myeloid malignancies: Myeloproliferative neoplasms, MDS/MPN, MDS.
• Laboratory diagnosis: Molecular genetics.
• General skills: Cellular and molecular biology of hematopoietic cells.